Literature DB >> 16048813

A brief overview of the clinical pharmacology of "club drugs".

Gena Covell Britt1, Elinore F McCance-Katz.   

Abstract

Four different "club drugs" are reviewed: MDMA (methylenedioxymethamphetamine, "Ecstasy"), GHB (gamma-hydroxybutyrate), ketamine, and Rohypnol (flunitrazepam). The neurobiology, clinical pharmacology, and treatment issues for each are discussed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16048813     DOI： 10.1081/JA-200066730

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN： 1082-6084            Impact factor:   2.164


  18 in total

Review 1.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

Review 2.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

3.  Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake.

Authors:  Samanta Yubero-Lahoz; K P C Kuypers; J G Ramaekers; Klaus Langohr; Magí Farré; Rafael de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2014-12-20       Impact factor: 4.530

Review 4.  Non-pharmacological factors that determine drug use and addiction.

Authors:  Serge H Ahmed; Aldo Badiani; Klaus A Miczek; Christian P Müller
Journal:  Neurosci Biobehav Rev       Date:  2018-09-01       Impact factor: 8.989

5.  Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, γ-hydroxybutyric acid.

Authors:  Nisha Vijay; Marilyn E Morris
Journal:  J Pharm Sci       Date:  2014-08-29       Impact factor: 3.534

Review 6.  Ketamine and the next generation of antidepressants with a rapid onset of action.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy Diazgranados; Carlos A Zarate
Journal:  Pharmacol Ther       Date:  2009-05-03       Impact factor: 12.310

Review 7.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

8.  Modulation of human risky decision making by flunitrazepam.

Authors:  Scott D Lane; Don R Cherek; Sylvain O Nouvion
Journal:  Psychopharmacology (Berl)       Date:  2007-10-05       Impact factor: 4.530

Review 9.  The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Neuroscientist       Date:  2009-05-26       Impact factor: 7.519

Review 10.  γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Authors:  Melanie A Felmlee; Bridget L Morse; Marilyn E Morris
Journal:  AAPS J       Date:  2021-01-08       Impact factor: 4.009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.